| Record Information |
| Version |
3.5 |
| Creation Date |
2005-11-16 08:48:42 -0700 |
| Update Date |
2013-02-08 17:09:08 -0700 |
| HMDB ID |
HMDB00707 |
| Secondary Accession Numbers |
None |
| Metabolite Identification |
| Common Name |
4-Hydroxyphenylpyruvic acid |
| Description |
4-Hydroxyphenylpyruvic acid (4-HPPA) is a keto acid that is involved in the tyrosine catabolism pathway. It is a product of the enzyme (R)-4-hydroxyphenyllactate dehydrogenase [EC 1.1.1.222] and is formed during tyrosine metabolism. The conversion from tyrosine to 4-HPPA is catalyzed by tyrosine aminotransferase. Additionally, 4-HPPA can be converted to homogentisic acid which is one of the precursors to ochronotic pigment. The enzyme 4-hydroxyphenylpyruvic acid dioxygenase (HPD) catalyzes the reaction that converts 4-hydroxyphenylpyruvic acid to homogentisic acid. A deficiency in the catalytic activity of HPD is known to lead to tyrosinemia type III, an autosomal recessive disorder characterized by elevated levels of blood tyrosine and massive excretion of tyrosine derivatives into urine. It has been shown that hawkinsinuria, an autosomal dominant disorder characterized by the excretion of 'hawkinsin,' may also be a result of HPD deficiency (PMID: 11073718 ). There are two isomers of HPPA, specifically 4HPPA and 3HPPA, of which 4HPPA is the most common. |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- (p-hydroxyphenyl)-Pyruvate
- (p-hydroxyphenyl)-Pyruvic acid
- (p-Hydroxyphenyl)pyruvate
- (p-Hydroxyphenyl)pyruvic acid
- 3-(4-Hydroxyphenyl)-2-oxo-propanoate
- 3-(4-Hydroxyphenyl)-2-oxo-propanoic acid
- 3-(4-Hydroxyphenyl)-2-oxopropionate
- 3-(4-Hydroxyphenyl)-2-oxopropionic acid
- 3-(4-Hydroxyphenyl)pyruvate
- 3-(4-Hydroxyphenyl)pyruvic acid
- 3-(p-Hydroxyphenyl)-2-oxopropionate
- 3-(p-Hydroxyphenyl)-2-oxopropionic acid
- 3-(p-Hydroxyphenyl)pyruvate
- 3-(p-Hydroxyphenyl)pyruvic acid
- 4-Hydroxy-a-oxobenzenepropanoate
- 4-Hydroxy-a-oxobenzenepropanoic acid
- 4-Hydroxy-alpha-oxobenzenepropanoate
- 4-Hydroxy-alpha-oxobenzenepropanoic acid
- 4-Hydroxyphenylpyruvate
- 4HPPA
- HPPA
- Hydroxyphenylpyruvate
- Hydroxyphenylpyruvic acid
- p-Hydroxyphenylpyruvic
- Testacid
|
| Chemical Formula |
C9H8O4 |
| Average Molecular Weight |
180.1574 |
| Monoisotopic Molecular Weight |
180.042258744 |
| IUPAC Name |
3-(4-hydroxyphenyl)-2-oxopropanoic acid |
| Traditional IUPAC Name |
3-(4-hydroxyphenyl)-2-oxopropanoic acid |
| CAS Registry Number |
156-39-8 |
| SMILES |
OC(=O)C(=O)CC1=CC=C(O)C=C1 |
| InChI Identifier |
InChI=1S/C9H8O4/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,10H,5H2,(H,12,13) |
| InChI Key |
KKADPXVIOXHVKN-UHFFFAOYSA-N |
| Chemical Taxonomy |
| Kingdom |
Organic Compounds |
| Super Class |
Aromatic Homomonocyclic Compounds |
| Class |
Benzyl Alcohols and Derivatives |
| Sub Class |
Phenylpyruvic Acid Derivatives |
| Other Descriptors |
- Organic Compounds
- oxo carboxylic acid(ChEBI)
|
| Substituents |
- Alpha Keto Acid
- Carboxylic Acid
- Ketone
- Phenol
- Phenol Derivative
|
| Direct Parent |
Phenylpyruvic Acid Derivatives |
| Ontology |
| Status |
Detected and Quantified |
| Origin |
|
| Biofunction |
Not Available |
| Application |
Not Available |
| Cellular locations |
|
| Physical Properties |
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
219 - 220 °C |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
Not Available |
Not Available |
| LogP |
Not Available |
Not Available |
|
| Predicted Properties |
|
| Spectra |
|
| Gas-MS Spectrum |
| 1H NMR Spectrum |
| MS/MS Spectrum Quattro_QQQ 10 |
| MS/MS Spectrum Quattro_QQQ 25 |
| MS/MS Spectrum Quattro_QQQ 40 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 10 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 20 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 30 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 40 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 50 |
| MS/MS Spectrum GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies ) |
| MS/MS Spectrum GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) |
| MS/MS Spectrum GC-MS |
| MS/MS Spectrum GC-MS |
| MS/MS Spectrum GC-MS |
| MS/MS Spectrum GC-MS |
| [1H,1H] 2D NMR Spectrum |
| [1H,13C] 2D NMR Spectrum |
|
| Biological Properties |
| Cellular Locations |
|
| Biofluid Locations |
|
| Tissue Location |
|
| Pathways |
|
| Normal Concentrations |
|
| Blood |
Detected and Quantified |
|
0.37 +/- 0.23 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
1.65 (0.15-8.74) umol/mmol creatinine |
Adult (>18 years old) |
Male |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
0.66 (0.23-2.50) umol/mmol creatinine |
Adult (>18 years old) |
Female |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
4.9 (4.9-4.9) umol/mmol creatinine |
Infant (0-1 year old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
4.6 (0.1-21.3) umol/mmol creatinine |
Newborn (0-30 days old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
1.8 (0.1-4.5) umol/mmol creatinine |
Children (1-13 year old) |
Both |
Normal |
Children aged 2-6 years
|
| Urine |
Detected and Quantified |
|
1.5 (0.6-3.4) umol/mmol creatinine |
Children (1-13 year old) |
Both |
Normal |
Children aged 6-10 years
|
| Urine |
Detected and Quantified |
|
1.8 (1.2-4.3) umol/mmol creatinine |
Adolescent (13-18 years old) |
Both |
Normal |
Children >10 years old
|
|
| Abnormal Concentrations |
|
| Urine |
Detected and Quantified |
|
1.00 (0.00-2.00) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Hawkinsinuria |
Not Available |
| Urine |
Detected and Quantified |
|
885.00 (170.00-1600.00) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Hawkinsinuria |
Not Available |
| Urine |
Detected and Quantified |
|
24.00 +/- 30.5 umol/mmol creatinine |
Newborn (0-30 days old) |
Both |
Phenylketonuria |
Not Available |
|
| Associated Disorders and Diseases |
| Disease References |
| Hawkinsinuria |
- http://www.metagene.de/program/d.prg?mp=HAWKINSINURIA
|
| Phenylketonuria |
- Monch E, Kneer J, Jakobs C, Arnold M, Diehl H, Batzler U: Examination of urine metabolites in the newborn period and during protein loading tests at 6 months of age--Part 1. Eur J Pediatr. 1990;149 Suppl 1:S17-24.
Pubmed: 2091926
|
|
| Associated OMIM IDs |
|
| External Links |
| DrugBank ID |
Not Available |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB022193 |
| KNApSAcK ID |
Not Available |
| Chemspider ID |
954  |
| KEGG Compound ID |
C01179  |
| BioCyc ID |
P-HYDROXY-PHENYLPYRUVATE  |
| BiGG ID |
37006  |
| Wikipedia Link |
Hydroxyphenylpyruvic acid  |
| NuGOwiki Link |
HMDB00707  |
| Metagene Link |
HMDB00707  |
| METLIN ID |
5675  |
| PubChem Compound |
979  |
| PDB ID |
ENO  |
| ChEBI ID |
15999  |
| References |
| Synthesis Reference |
Billek, Gerhard. p-Hydroxyphenylpyruvic acid. Organic Syntheses (1963), 43 49-54. |
| Material Safety Data Sheet (MSDS) |
Download (PDF)
|
| General References |
- Shoda J, Tanaka N, Osuga T, Matsuura K, Miyazaki H: Altered bile acid metabolism in liver disease: concurrent occurrence of C-1 and C-6 hydroxylated bile acid metabolites and their preferential excretion into urine. J Lipid Res. 1990 Feb;31(2):249-59.
Pubmed: 2324645
- Wolff JA, Barshop B, Nyhan WL, Leslie J, Seegmiller JE, Gruber H, Garst M, Winter S, Michals K, Matalon R: Effects of ascorbic acid in alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy. Pediatr Res. 1989 Aug;26(2):140-4.
Pubmed: 2771520
- Deutsch JC: Determination of p-hydroxyphenylpyruvate, p-hydroxyphenyllactate and tyrosine in normal human plasma by gas chromatography-mass spectrometry isotope-dilution assay. J Chromatogr B Biomed Sci Appl. 1997 Mar 7;690(1-2):1-6.
Pubmed: 9106023
- Guneral F, Bachmann C: Age-related reference values for urinary organic acids in a healthy Turkish pediatric population. Clin Chem. 1994 Jun;40(6):862-6.
Pubmed: 8087979
- Muskiet FA, Fremouw-Ottevangers DC, Nagel GT, Wolthers BG, de Vries JA: Determination of 3-methoxy-4-hydroxyphenylpyruvic acid, 3,4-dihydroxyphenylethylene glycol, and 3,4-dihydroxyphenylmandelic acid in urine by mass fragmentography, with use of deuterium-labeled internal standards. Clin Chem. 1978 Nov;24(11):2001-8.
Pubmed: 709835
- Endo F, Katoh H, Yamamoto S, Matsuda I: A murine model for type III tyrosinemia: lack of immunologically detectable 4-hydroxyphenylpyruvic acid dioxygenase enzyme protein in a novel mouse strain with hypertyrosinemia. Am J Hum Genet. 1991 Apr;48(4):704-9.
Pubmed: 2014797
- Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4.
Pubmed: 19212411
|